MICM
RDY icon

Matthews International Capital Management’s Dr. Reddy's Laboratories RDY Stock Holding History

Matthews International Capital Management’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-48,000
Closed -$589K – 54
2021
Q1 		$589K Buy
48,000
+14,000
+41% +$180K 0.02% 49
2020
Q4 		$485K Buy
34,000
+9,500
+39% +$128K 0.03% 39
2020
Q3 		$341K Buy
+24,500
New +$292K 0.02% 30

Other funds holding RDY

Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Matthews International Capital Management's RDY Position: Q2 2021 in Review

Matthews International Capital Management sold out of Dr. Reddy's Laboratories (RDY) in Q2 2021, closing a stake of 48,000 shares — an estimated $589K sold.

Matthews International Capital Management first reported a position in RDY in Q3 2020 and held it in 3 quarters. The position peaked at $589K in Q1 2021. 161 funds tracked by Wall St. Rank hold RDY as of Q2 2021.

  • Matthews International Capital Management reported no remaining Dr. Reddy's Laboratories position as of Q2 2021 after selling out during the quarter.
  • Matthews International Capital Management sold 48,000 Dr. Reddy's Laboratories shares in Q2 2021, an estimated $589K.
  • Matthews International Capital Management first reported a position in Dr. Reddy's Laboratories in Q3 2020 and held it in 3 quarters.
  • Matthews International Capital Management's Dr. Reddy's Laboratories position peaked at $589K in Q1 2021.
  • 161 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2021.

Based on Matthews International Capital Management's 13F filing for Q2 2021, filed 10 Aug 2021.